Dry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage Study

OKYO Pharma Limited OKYO announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive safety profile in the ongoing study. 

Patients continue in the study, and double-blind procedures are still in effect until all patients complete the 12-week dosing duration. 

OKYO will continue to monitor the trial progress and the safety profile until the release of top-line data in December 2023.

The assignment of 240 DED patients to treatment is complete, with 230 (95%) patients having completed four weeks of dosing, 174 patients (72%) completing eight weeks, and 17 patients completing 12 weeks of dosing. 

OK-101 is well tolerated, with patients continuing on the trial without a dose change.

The company expects the last-patient last-visit to occur in the last week of November 2023, with the planned release of top-line data occurring in December 2023.

DED is a common condition when one's tears cannot adequately lubricate the eyes. This condition affects approximately 49 million people in the United States alone and has been difficult to positively diagnose and treat due to the multifactorial nature of the condition. 

Price Action: OKYO shares are down 17.60% at $2.29 on the last check Thursday.